Protect Pharmaceutical(PRTT)
$0.06+0.00 (+1.69%)
PRTT
Protect Pharmaceutical financials statements
$0.06
At close:+0.00 (+1.69%)
Protect Pharmaceutical (PRTT) Ratios
18 Followers
Protect Pharmaceutical Ratios
PRTT's free cash flow for Q2 2025 was $-4.57M. For the 2025 fiscal year, PRTT's free cash flow was decreased by $-2.47M and operating cash flow was $-2.10M. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.06 | 2.36 | 1.55 | 0.96 | 1.48 |
| Quick Ratio | 1.67 | 1.44 | 0.83 | 0.64 | 1.48 |
| Cash Ratio | 0.21 | 0.20 | 0.01 | 0.25 | 1.48 |
| Solvency Ratio | 0.66 | 0.51 | 0.20 | 0.13 | 0.43 |
| Operating Cash Flow Ratio | 0.15 | 0.04 | -0.59 | 0.07 | 134.63 |
| Short-Term Operating Cash Flow Coverage | 3.32 | 1.07 | -25.30 | 0.85 | 0.00 |
| Net Current Asset Value | $ 175.03M | $ 122.62M | $ 63.37M | $ -7.04M | $ -14.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.03 | 0.70 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.06 | 2.39 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.06 | 0.70 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.70 |
| Financial Leverage Ratio | 1.26 | 1.33 | 1.50 | 1.78 | 3.40 |
| Debt Service Coverage Ratio | 14.71 | 12.15 | 8.54 | 1.66 | 4228.71 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 4228.71 |
| Debt to Market Cap | 0.12 | 0.03 | 0.34 | 0.55 | 0.21 |
| Interest Debt Per Share | 0.07 | 0.07 | 0.05 | 0.22 | 0.26 |
| Net Debt to EBITDA | -0.24 | -0.30 | 0.06 | -0.98 | 2.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.86% | 53.84% | 50.83% | 56.31% | 98.68% |
| EBIT Margin | 43.58% | 34.92% | 30.88% | 35.38% | 97.87% |
| EBITDA Margin | 43.58% | 35.04% | 31.16% | 35.68% | 97.87% |
| Operating Profit Margin | 43.58% | 34.92% | 30.88% | 35.38% | 97.87% |
| Pretax Profit Margin | 43.58% | 34.92% | 30.88% | 35.38% | 97.85% |
| Net Profit Margin | 42.59% | 33.72% | 27.44% | 25.65% | 97.85% |
| Continuous Operations Profit Margin | 42.59% | 33.72% | 27.44% | 25.65% | 97.85% |
| Net Income Per EBT | 97.72% | 96.58% | 88.85% | 72.49% | 100.00% |
| EBT Per EBIT | 100.00% | 100.00% | 100.00% | 100.00% | 99.98% |
| Return on Assets (ROA) | 13.49% | 12.53% | 6.52% | 5.52% | 29.04% |
| Return on Equity (ROE) | 16.93% | 16.61% | 9.76% | 9.83% | 98.70% |
| Return on Capital Employed (ROCE) | 17.33% | 17.20% | 10.98% | 13.56% | 29.12% |
| Return on Invested Capital (ROIC) | 16.74% | 16.39% | 9.65% | 9.27% | 29.12% |
| Return on Tangible Assets | 13.64% | 12.68% | 6.60% | 5.98% | 29.04% |
| Earnings Yield | 173.22% | 30.86% | 283.47% | 89.81% | 8.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.95 | 2.11 | 1.70 | 3.15 | 0.00 |
| Payables Turnover | 12.63 | 15.03 | 13.17 | 68.86 | 40.30 |
| Inventory Turnover | 0.50 | 0.76 | 0.48 | 0.67 | 0.00 |
| Fixed Asset Turnover | 0.95 | 0.96 | 0.55 | 0.46 | 0.30 |
| Asset Turnover | 0.32 | 0.37 | 0.24 | 0.22 | 0.30 |
| Working Capital Turnover Ratio | 0.89 | 1.46 | 2.90 | -22.46 | -299.28 |
| Cash Conversion Cycle | 881.41 | 631.04 | 940.74 | 653.06 | -9.06 |
| Days of Sales Outstanding | 186.76 | 172.61 | 215.30 | 115.81 | 0.00 |
| Days of Inventory Outstanding | 723.54 | 482.72 | 753.15 | 542.55 | 0.00 |
| Days of Payables Outstanding | 28.89 | 24.29 | 27.70 | 5.30 | 9.06 |
| Operating Cycle | 910.30 | 655.33 | 968.45 | 658.36 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.22 | 0.07 | -1.27 | 0.19 | 0.12 |
| Free Cash Flow Per Share | 0.18 | 0.00 | -1.31 | -1.15 | -0.24 |
| Dividend Paid and CapEx Coverage Ratio | 5.03 | 1.00 | -36.96 | 0.14 | 0.34 |
| Capital Expenditure Coverage Ratio | 5.03 | 1.00 | -36.96 | 0.14 | 0.34 |
| Operating Cash Flow Coverage Ratio | 3.32 | 1.07 | -25.30 | 0.85 | 0.48 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.03 | -0.82 | 0.13 | 1.14 |
| Free Cash Flow Yield | 31.33% | 0.00% | -871.76% | -288.43% | -19.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 0.58 | 3.24 | 0.35 | 1.11 | 11.34 |
| Price-to-Sales (P/S) Ratio | 0.25 | 1.09 | 0.10 | 0.29 | 11.10 |
| Price-to-Book (P/B) Ratio | 0.10 | 0.54 | 0.03 | 0.11 | 11.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 3.19 | 0.00 | -0.11 | -0.35 | -5.06 |
| Price-to-Operating Cash Flow Ratio | 2.56 | 36.81 | -0.12 | 2.14 | 9.73 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 |
| Enterprise Value Multiple | 0.32 | 2.82 | 0.37 | -0.18 | 13.75 |
| Enterprise Value | 18.68M | 134.37M | 9.37M | -5.07M | 79.94M |
| EV to EBITDA | 0.32 | 2.82 | 0.37 | -0.18 | 13.75 |
| EV to Sales | 0.14 | 0.99 | 0.11 | -0.06 | 13.46 |
| EV to Free Cash Flow | 1.83 | 0.00 | -0.14 | 0.08 | -6.14 |
| EV to Operating Cash Flow | 1.47 | 33.24 | -0.14 | -0.48 | 11.80 |
| Tangible Book Value Per Share | 5.71 | 4.74 | 4.27 | 3.15 | 0.11 |
| Shareholders’ Equity Per Share | 5.79 | 4.81 | 4.36 | 3.66 | 0.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.03 | 0.11 | 0.28 | 0.00 |
| Revenue Per Share | 2.30 | 2.37 | 1.55 | 1.40 | 0.11 |
| Net Income Per Share | 0.98 | 0.80 | 0.43 | 0.36 | 0.11 |
| Tax Burden | 0.98 | 0.97 | 0.89 | 0.72 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.02 | 0.04 | 0.02 | 0.02 | 0.00 |
| SG&A to Revenue | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.23 | 0.09 | -2.99 | 0.52 | 1.17 |
Currency in USD
